Cargando…

Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review

Acute graft-versus-host disease (GVHD) remains a barrier to successful allogeneic hematopoietic cell transplantation (HCT) outcomes. This multicenter, retrospective chart review describes disease progression, treatment patterns, hospitalizations, and clinical outcomes among 475 patients (≥12 years o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holtan, Shernan G., Yu, Jingbo, Choe, Hannah K., Paranagama, Dilan, Tang, Jackson, Naim, Ahmad, Galvin, John, Joachim Deeg, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576589/ https://www.ncbi.nlm.nih.gov/pubmed/35908108 http://dx.doi.org/10.1038/s41409-022-01764-w

Ejemplares similares

Correction to: Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review
por: Holtan, Shernan G., et al.
Publicado: (2022)

Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study
por: Holtan, Shernan G., et al.
Publicado: (2022)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
por: Yu, Jingbo, et al.
Publicado: (2018)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Recruitment strategies and geographic representativeness for patient survey studies in rare diseases: Experience from the living with myeloproliferative neoplasms patient survey
por: Yu, Jingbo, et al.
Publicado: (2020)

Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
por: Holtan, Shernan G., et al.
Publicado: (2023)

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Solid Organ Transplant Graft-Versus-Host Disease in a Kidney/Pancreas Transplant Patient: Use of Chimerism Testing and a Rare Presentation of Cutaneous GVHD
por: Goyal, Amrita, et al.
Publicado: (2022)

Graft-versus-host disease: teaching old drugs new tricks at less cost
por: Farhan, Shatha, et al.
Publicado: (2023)

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey
por: Yu, Jingbo, et al.
Publicado: (2019)

The utility of biomarkers in acute GVHD prognostication
por: Spyrou, Nikolaos, et al.
Publicado: (2023)

Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting
por: Afram, Gabriel, et al.
Publicado: (2018)

Milestones in acute GVHD pathophysiology
por: Socie, Gerard, et al.
Publicado: (2022)

Cytoreductive treatment patterns among US veterans with polycythemia vera
por: Parasuraman, Shreekant, et al.
Publicado: (2018)

Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data
por: Parasuraman, Shreekant, et al.
Publicado: (2019)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
por: Watson, Allison P., et al.
Publicado: (2018)

Progress of cGVHD pathogenesis from the perspective of B cells
por: Li, Xiaoping, et al.
Publicado: (2019)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort
por: Cruz, Conrad Russell Y., et al.
Publicado: (2021)

Do Cancer and Cancer Treatments Accelerate Aging?
por: Bhatia, Roma, et al.
Publicado: (2022)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Targeting Cytokines in GVHD Therapy
por: Kumar, Sandeep, et al.
Publicado: (2017)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
por: El Jurdi, Najla, et al.
Publicado: (2023)

Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2015)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial
por: Holtan, Shernan G., et al.
Publicado: (2012)

Roles of the intestinal microbiota and microbial metabolites in acute GVHD
por: Lin, Dandan, et al.
Publicado: (2021)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022)

Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
por: Hildebrandt, G C, et al.
Publicado: (2011)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States
por: Verstovsek, Srdan, et al.
Publicado: (2020)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rvaqb2kes01budoutjlrojdpdo